As gene editing technologies evolve, the number of potential engineered cell-based treatments continues to increase. With tools such as CRISPR and TARGATT^TM, it is easier than ever before to insert chimeric antigen receptor (CAR) genes into iPSCs that can be further differentiated into natural killer (NK) or T cells. While there is still plenty of cancer immunotherapy research to be done, CAR-iNK and CAR-iT cell engineering provides a great opportunity for the development of therapeutics that could potentially target and eliminate various forms of cancer. These new cell therapies could be revolutionary, but before entering clinical trials, it is important to ensure these candidates are effective and safe.

Whether you are looking to start your in vitro experiments or in vivo preclinical studies, Applied StemCell can help you design the right efficacy, safety, or toxicity assay for your cancer immunotherapy research. ASC offers a series of customizable iPSC-based CAR-NK and CAR-T cell assay services. Our team has several years of experience working with iPSCs and iPSC-derived products, so we guarantee we can create assays that capture all your requirements and deliver detailed intermediate and final reports with essential quantitative data for your preclinical studies.

• Fully Customizable
• In vivo and in vitro efficacy, safety, and toxicity preclinical studies
• In vitro Assays: humanized mouse models engineered in the U.S.A.
• Fast & Affordable

As a leading iPSC CRO/CDMO, we also offer iPSC differentiation services to NK and T cells from your healthy/disease iPSCs or our well-characterized control lines. Our experts can even use our proprietary knock-in technology, TARGATT™ to integrate your CAR gene(s) onto your iPSCs prior to the differentiation process. Additionally, we can assist in the optimization of your CAR design to increase expression. If you would like to learn more, contact us today or visit our TARGATT™ iPSC-iNK Platform page for more details.

Ask an Expert